Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Seattle-based Juno Therapeutics is leasing a building in Bothell, Wash., where it plans to install manufacturing capacity to support cell therapies in its pipeline. Juno launched in late 2013 to develop therapies based on chimeric antigen receptor T-cell (CART) technology, a type of immunotherapy that reengineers a patient’s own T cells to home in on cancer cells. Expected to be completed in early 2016, the Bothell site will support Juno’s clinical trials for JCAR015, a CART currently in Phase I studies in acute lymphoblastic leukemia and non-Hodgkin lymphoma.
This article has been sent to the following recipient: